Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neuromuscular Diseases: full-pipeline trial registry
8 of 16 indexed Neuromuscular Diseases trials are currently recruiting.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 8 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Neuromuscular Diseases: 16 US clinical trials tracked, 8 recruiting.
Neuromuscular Diseases is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Scholar Rock, running 3 of these trials.
Enrollment posture brief
Registry condition neuromuscular-diseases
OPEN 8 | RECR 50% | LATE 4 | EARLY 4 | RANK #1060 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Neuromuscular Diseases lists 8 open slots (50% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neuromuscular Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neuromuscular Diseases is recruiting above its size-band peers.
8 of 16 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neuromuscular Diseases research.
Scholar Rock accounts for 3 of 16 trials (18.8%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Neuromuscular Diseases enrolment sits around 90 participants.
Median target enrolment is 90 among the 16 trials that report a genuine target (sentinel values excluded). 9 of those (56.3%) plan for fewer than 100 participants.
-
Neuromuscular Diseases splits between interventional and observational designs.
10 interventional and 6 observational studies make up this index (62.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
CIMR Neuromuscular Research Biobank
Virginia Commonwealth University
NCT05434572
Spastic Paraplegia - Centers of Excellence Research Network
Boston Children's Hospital
NCT06553976
Genesis Electrical Impedance Tomography (EIT): A Preliminary Study
University of Colorado, Denver
NCT03797183
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
Satellos Bioscience
NCT07287189
Measuring Physical Activity With ActivPal
Columbia University
NCT06084026
A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J
Elpida Therapeutics SPC
NCT06151600
Non-Invasive Respiratory Monitor
Nemours Children's Clinic
NCT02851043
Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study
University of Pennsylvania
NCT06119087
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
Biohaven Pharmaceuticals
NCT05337553
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
Scholar Rock
NCT05626855
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Capricor
NCT05126758
Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
ZS Associates
NCT06381284
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
Scholar Rock
NCT05156320
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
Scholar Rock
NCT03921528
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
Avidity Biosciences
NCT05479981
Study of Pioglitazone in Sporadic Inclusion Body Myositis
Johns Hopkins University
NCT03440034
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Neuromuscular Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neuromuscular Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neuromuscular Diseases page
16 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Neuromuscular Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Scholar Rock sponsors the most Neuromuscular Diseases trials on record, review their full trial history before evaluating a specific study. See Scholar Rock's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuromuscular Diseases condition card totals 16 registered trials; most-linked intervention Placebo; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.